Published in Curr Drug Targets on June 01, 2012
Next generation sequencing improves the accuracy of KRAS mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions. PLoS One (2014) 0.93
A mathematical model for pancreatic cancer growth and treatments. J Theor Biol (2014) 0.82
The tumor suppressor rpl36 restrains KRAS(G12V)-induced pancreatic cancer. Zebrafish (2014) 0.79
ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma. Cancer Sci (2016) 0.75
Exome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient. Onco Targets Ther (2014) 0.75
APC promoter is frequently methylated in pancreatic juice of patients with pancreatic carcinomas or periampullary tumors. Oncol Lett (2016) 0.75
Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma. Oncotarget (2017) 0.75
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol (2010) 24.32
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
miRNAs, cancer, and stem cell division. Cell (2005) 12.15
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA (2007) 9.97
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Pancreatic cancer biology and genetics. Nat Rev Cancer (2002) 7.36
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer (2007) 6.57
Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol (2001) 6.30
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene (2007) 4.46
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther (2007) 3.61
MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) (2009) 3.55
Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol (2006) 3.37
Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol (2006) 3.24
Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol (2005) 3.20
The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol (1990) 3.20
Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol (2007) 2.98
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg (2001) 2.94
Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res (2007) 2.92
Stromal biology of pancreatic cancer. J Cell Biochem (2007) 2.88
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol (2008) 2.81
LigAmp for sensitive detection of single-nucleotide differences. Nat Methods (2004) 2.70
Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics (2005) 2.66
Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am J Pathol (2000) 2.63
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther (2009) 2.61
Biology and management of pancreatic cancer. Gut (2007) 2.53
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol (2008) 2.46
Precursors to invasive pancreatic cancer. Adv Anat Pathol (2005) 2.45
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res (2006) 2.38
N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res (2004) 2.35
Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol (2007) 2.35
Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology (2005) 2.21
Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer (2005) 2.20
MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer (2007) 2.19
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res (2004) 2.06
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One (2010) 1.96
Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol (2009) 1.94
Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol (2007) 1.94
Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res (2006) 1.93
Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res (2004) 1.93
Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg (2008) 1.93
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer (2007) 1.87
Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol (2008) 1.87
Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol (2010) 1.82
Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Proteome Res (2010) 1.81
Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res (2002) 1.81
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer (2007) 1.77
Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br J Cancer (2004) 1.77
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2004) 1.76
Differentiating pancreatic lesions by microarray and QPCR analysis of pancreatic juice RNAs. Cancer Biol Ther (2006) 1.74
Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res (2004) 1.74
Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol (2007) 1.73
MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer (2010) 1.66
Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology (2005) 1.61
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer (2007) 1.58
Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology (2006) 1.58
Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia (2009) 1.52
Role of tumour markers, cytogenetics. Ann Oncol (1999) 1.51
Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev (2008) 1.38
Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev (1998) 1.36
Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas (2007) 1.35
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer (2005) 1.34
CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem (1998) 1.31
Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am (2002) 1.30
Diagnosis of pancreatic cancer. HPB (Oxford) (2006) 1.29
Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma. Pancreas (2009) 1.29
Pancreatic head cancer: accuracy of CT in determination of resectability. Abdom Imaging (2005) 1.24
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther (2006) 1.22
Twist, a novel oncogene, is upregulated in pancreatic cancer: clinical implication of Twist expression in pancreatic juice. Int J Cancer (2007) 1.19
Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era? J Am Coll Surg (2009) 1.18
Role of tumor markers in patients with solid cancers: A critical review. Eur J Intern Med (2007) 1.07
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer (2009) 1.05
Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br J Cancer (2010) 0.97
Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas. Int J Cancer (2007) 0.91
MicroRNAs linked to pancreatic cancer. JAMA (2007) 0.85
Pancreatic endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy (2007) 0.84
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
International network of cancer genome projects. Nature (2010) 20.35
EGFR antagonists in cancer treatment. N Engl J Med (2008) 9.68
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol (2006) 5.40
Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol (2003) 4.31
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res (2002) 3.33
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther (2008) 2.99
Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol (2009) 2.94
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res (2005) 2.60
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2007) 2.47
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res (2004) 2.47
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res (2003) 2.26
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol (2013) 2.26
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res (2002) 2.01
Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res (2007) 1.98
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology (2009) 1.92
Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut (2006) 1.91
Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. J Rheumatol (2007) 1.87
Establishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell lymphoma. Haematologica (2006) 1.84
Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Proteome Res (2010) 1.81
Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene (2002) 1.67
HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood (2005) 1.62
Mutational profile of GNAQQ209 in human tumors. PLoS One (2009) 1.62
DNA qualification workflow for next generation sequencing of histopathological samples. PLoS One (2013) 1.57
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res (2008) 1.56
Gastrinoma (duodenal and pancreatic). Neuroendocrinology (2007) 1.55
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Endocrine neoplasms of the pancreas: pathologic and genetic features. Arch Pathol Lab Med (2009) 1.46
Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer (2003) 1.44
Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. Eur Urol (2004) 1.43
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res (2002) 1.43
Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol (2011) 1.42
Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest (2008) 1.42
Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology (2007) 1.40
MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer (2010) 1.38
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta (2007) 1.38
Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. Haematologica (2008) 1.35
Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol (2014) 1.33
Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol (2006) 1.33
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One (2013) 1.32
Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr Relat Cancer (2005) 1.30
The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Crit Rev Oncol Hematol (2008) 1.30
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer (2010) 1.28
Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells. Biosci Rep (2011) 1.28
Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery (2006) 1.25
Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer (2014) 1.24
Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer (2006) 1.22
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation (2007) 1.19
Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery (2011) 1.15
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget (2014) 1.14
Chromosomal alterations detected by comparative genomic hybridization in nonfunctioning endocrine pancreatic tumors. Cancer Genet Cytogenet (2005) 1.14
Prognostic relevance of lymph node ratio and number of resected nodes after curative resection of ampulla of Vater carcinoma. Ann Surg Oncol (2008) 1.13
MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat (2010) 1.13
Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta (2004) 1.12
ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung. J Thorac Oncol (2014) 1.11
Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch (2006) 1.09
Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB J (2005) 1.09
Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs (2002) 1.08
Intraductal papillary mucinous neoplasms and chronic pancreatitis. Pancreatology (2006) 1.08
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother (2013) 1.08
MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines. Nucleic Acids Res (2009) 1.08
Genetic abnormalities in pancreatic cancer. Mol Cancer (2003) 1.07
Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog (2003) 1.07
Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene (2005) 1.06
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer (2009) 1.05
Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res (2006) 1.05
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res (2005) 1.04
SEL1L a multifaceted protein playing a role in tumor progression. J Cell Physiol (2006) 1.03
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin Ther Targets (2011) 1.03
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol (2013) 1.02
Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood (2003) 1.02
Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer (2011) 1.02
Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol (2007) 1.02
Multicentre validation study of nucleic acids extraction from FFPE tissues. Virchows Arch (2010) 1.01
Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. Virchows Arch (2003) 1.01
SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo. Oncogene (2003) 1.01
K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. Mod Pathol (2004) 1.01
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clin Cancer Res (2011) 1.00
Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. J Exp Clin Cancer Res (2011) 1.00
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. Gastric Cancer (2013) 1.00
Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas. Haematologica (2004) 0.99
Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung. Anticancer Res (2010) 0.98
Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res (2007) 0.98
Aggressive approach to acinar cell carcinoma of the pancreas: a single-institution experience and a literature review. Langenbecks Arch Surg (2010) 0.98
Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism. Clin Cancer Res (2003) 0.98
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. Hum Mutat (2009) 0.97